Postinflammatory hyperpigmentation - Hyperpigmentation Postinflammatory
Is coinníoll cutaneous é Hyperpigmentation Postinflammatory (Postinflammatory hyperpigmentation) arb é is sainairíonna é go bhfuil méadú ar lí sa chraiceann tar éis athlasadh an chraiceann. Is féidir le hyperpigmentation postinflammatory (postinflammatory hyperpigmentation) a bheith ina chúis le nochtadh fada gréine, athlasadh, nó gortuithe craiceann eile, lena n-áirítear iad siúd a bhaineann le acne. Is gnách go mbíonn daoine a bhfuil toin chraiceann níos dorcha acu níos mó seans maith go hipearpigmentation le barraíocht nochta don ghrian.
☆ I dtorthaí 2022 Stiftung Warentest ón nGearmáin, ní raibh sástacht na dtomhaltóirí le ModelDerm ach beagán níos ísle ná mar a bhí le comhairliúchán teileamhíochaine íoctha.
References
Postinflammatory hyperpigmentation (PIH) Is fadhb craicinn go minic a tharlaíonn tar éis athlasadh craicinn nó gortaithe. Is gnách go mairfidh sé ar feadh i bhfad agus bíonn sé níos measa i ndaoine a bhfuil toin chraiceann níos dorcha acu (Fitzpatrick skin types III–VI) . Cé go n-éiríonn sé níos fearr leis féin go minic, is féidir go dtógfadh sé seo tamall, agus mar sin is minic go mbíonn gá le cóireáil ar feadh i bhfad. Is fearr cóireálacha éagsúla a chomhcheangal.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Is sequelae coitianta athlasadh craiceann é Postinflammatory hyperpigmentation. Is minic a théann sé i bhfeidhm ar dhaoine a bhfuil craiceann níos dorcha orthu. Léiríonn staidéir go bhfuil saincheisteanna cosúil le postinflammatory hyperpigmentation i measc na bpríomhchúiseanna a lorgaíonn daoine le tones craiceann níos dorcha cúram dermatological. Tá cóireáil luath ríthábhachtach chun postinflammatory hyperpigmentation a réiteach agus de ghnáth tosaíonn sé leis an riocht athlastach tosaigh a bhainistiú. Is éard atá i gceist leis an gcéad líne cóireála de ghnáth ag baint úsáide as oibreáin tráthúla a éadromaíonn an craiceann mar aon le grianscéithe le haghaidh cosanta. Is féidir leis na gníomhairí seo, cosúil le hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , laghdú éifeachtach a dhéanamh ar lí iomarcach. Ina theannta sin, baintear úsáid as retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy mar oibreáin dhídhírithe, agus cóireálacha nua ag teacht chun cinn. Cé go mbíonn cóireálacha tráthúla éifeachtach de ghnáth le haghaidh hipearpigmentation ar leibhéal an dromchla, d’fhéadfadh go mbeadh gá le nósanna imeachta (laser, chemical peel) le haghaidh cásanna stubborn. Tá sé tábhachtach a bheith cúramach leis na cóireálacha seo chun greannú agus dul in olcas postinflammatory hyperpigmentation a sheachaint.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
